Detalles de la búsqueda
1.
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).
Int J Cancer
; 150(1): 112-123, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34431518
2.
Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry.
Int J Cancer
; 148(6): 1478-1488, 2021 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33038277
3.
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.
Ann Hematol
; 98(4): 897-907, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30610279
4.
Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial.
Int J Cancer
; 142(5): 1047-1055, 2018 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29047142
5.
Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer--results from a non-interventional observation study.
BMC Cancer
; 16: 82, 2016 Feb 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-26865161
6.
Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer.
Breast Cancer Res Treat
; 149(1): 141-9, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25519041
7.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 15(10): 1065-75, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25088940
8.
Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype.
Blood
; 119(9): 2122-5, 2012 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22207733
9.
A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma.
Eur J Cancer
; 196: 113436, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38008033
10.
Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial.
J Clin Oncol
; 36(20): 2024-2034, 2018 07 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29750632
11.
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
JAMA Oncol
; 3(9): 1237-1244, 2017 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28448662
12.
Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL.
Springerplus
; 3: 5, 2014 Jan 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-24455463
13.
A novel germline KIT mutation (p.L576P) in a family presenting with juvenile onset of multiple gastrointestinal stromal tumors, skin hyperpigmentations, and esophageal stenosis.
Am J Surg Pathol
; 37(6): 898-905, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23598963
Resultados
1 -
13
de 13
1
Próxima >
>>